spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Registration Opens for Inaugural HPAPI USA Conference in October

Registration is now open for the HPAPI USA conference, taking place in Boston on the 21st-22nd October 2019

SMi reports: Registration is now open for the HPAPI USA conference, taking place in Boston on the 21st-22nd October 2019.

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.

With this in mind, SMi Group are pleased to present the inaugural HPAPI USA conference, taking place in Boston on the 21st-22nd October 2019.

The two-day event will explore how current technologies are streamlining the HPAPI industry with artificial intelligence and machine learning to improve risk assessment and validation, as well as the latest emerging therapies including bispecific antibodies, oncolytic viral complexes and hormones.

For those interested in attending, there is a $400 early bird discount on bookings expiring on May 31st, 2019. Places can be reserved at http://www.hpapi-usa.com

Key Highlights include:

• Oncology Antibody-Drug Conjugates (ADC), the ongoing developments and the containment challenges imposed
• How to correctly assess, plan and implement the most cost-effective containment
• Emerging HPAPI therapies, oncolytic viruses their potential and challenges
• Alternative HPAPI manufacturing technologies to reduce powder exposure and improving safety along with enabling continuous manufacturing
• The reality of oncology ADC and HPAPI: are most drugs using ‘highly-potent’ to improve brand image? Has 50 years of ADC R&D for oncology with no cure shows signs of no promise?

The agenda features presentations from key opinion leaders from all areas of pharmaceuticals and biologicals to share strategies on developing containment, formulation and manufacturing for maximum HPAPI success.

Chairs for 2019:

Janet Gould, Senior Managing Toxicologist, SafeBridge Consultants USA
Rakesh Dixit, Vice President of R&D Global Head, MedImmune; Vice President of R&D Translational Sciences – Biologics Safety Assessment, AstraZeneca

Featured speakers include:

Charlyn Reihman, Principal Occupational Health Consultant, SafeBridge Consultants USA
David Eherts, Vice President, Global EHS, Allergan
Keith Jensen, Owner and Consultant, Keith Jensen Consulting, Formerly at Novartis-MITCenter for Continuous Manufacturing
Tony Haight, Director of Process Chemistry, AbbVie
Sara Martens, Senior Manager EHS Technical Operations, AbbVie

The event brochure with the full agenda and speaker line-up is available to download online at http://www.hpapi-usa.com/pr

HPAPI USA 2019 is proudly sponsored by Lonza and SafeBridge Consultants, Inc.

SMi offer unique sponsorship, exhibition and branding packages, tailored to complement your company’s marketing strategy. Contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 / Email: nhoward@smi-online.co.uk

HPAPI USA
Conference: 21st- 22nd October 2019
Workshops: 23rd October 2019
Sheraton Boston Hotel, Boston, USA
#smihpapi-usa

---END---

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>


White Papers

Exploring Protein Stability by nanoDSF

NanoTemper Technologies GmbH

nanoDSF determines thermal and chemical protein stability with ultra-high resolution and with unmatched reproducibility. The detection of the intrinsic tryptophan and tyrosin fluorescence enables measurements at close-to-native conditions in any buffer, even in the presence of detergents. nanoDSF is applied in antibody engineering, membrane protein research, formulation and quality control.
More info >>

Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement